Why the study?
Does SCH 42495 reduce blood pressure in patients with essential hypertension?
Population
27 patients with essential hypertension (WHO Stage I or II), mean age 64 +/- 1 years.
Design
Cohort, open-label
Follow-up
8 weeks
Authors
Loading...
Supports further evaluation of SCH 42495 in essential hypertension; leaves open confirmation of efficacy and safety in randomized trials.
Does SCH 42495 reduce blood pressure in patients with essential hypertension?
The novel neutral endopeptidase inhibitor SCH 42495 significantly reduces blood pressure in essential hypertension, though its use may be limited by adverse effects such as headaches and palpitations.
Ogihara et al. (1994) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: